Bell Potter Healthcare Conference
Logotype for Telix Pharmaceuticals Limited

Telix Pharmaceuticals (TLX) Bell Potter Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Telix Pharmaceuticals Limited

Bell Potter Healthcare Conference summary

18 Nov, 2026

Commercial platform and outlook

  • Three FDA-approved precision medicine products serve prostate and brain cancer; commercial sales span 22 countries, supported by 45 manufacturing sites globally.

  • 2026 revenue expected just under US$1 billion, with guidance projected at the top end; precision medicine revenue is expected to grow more than 25% YoY.

  • Radiopharma growth drivers targeted for 2027 include Illuccix and Gozellix, new products and indications, expansion into China and Japan, Telix Manufacturing Solutions revenue, and ITM assets.

  • ITM acquisition is intended to secure lutetium supply and add complementary pipeline assets; settlement is due early in 2027.

BiPASS prostate study

  • Phase III BiPASS compares gallium PSMA PET plus MRI with MRI alone for detecting clinically significant prostate cancer; 350 patients enrolled at U.S. and Australian sites, with enrollment completed in June.

  • The trial builds on PRIMARY2 findings that PSMA PET could help roughly half of patients avoid biopsy without missing clinically significant cancer; its FDA-negotiated design is intended to generate submission-ready data.

  • Six-month follow-up puts study data due around Q1 2027; a new drug application is planned for Q2 2027, following granted fast-track designation.

  • Starting in 2027, PSMA PET plus MRI is expected to support biopsy avoidance for suitable patients and more targeted biopsies for others.

Pixclara and brain imaging

  • FDA approved Pixclara, a FET PET imaging agent, in September for assessing suspected recurrent glioma after initial treatment; commercial use has begun.

  • Pixclara currently uses a not-otherwise-classified reimbursement code; a temporary pass-through code is expected in Q1 2027, when broader commercial scale-up is anticipated.

  • A Phase III trial is about to start to pursue a brain-metastases indication, a market described as about 10 times the size of primary brain cancer.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Telix Pharmaceuticals